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To identify Fc γ RIIA genotypes in Systemic Lupus Erythematosus (SLE) patients and their association with anti-C1q antibodies.
Methods.F cγ RIIA genotyping was done in eighty Indian SLE patients and eighty healthy controls using allele-speciﬁc PCR.
Anti-C1q antibodies were measured by ELISA. Results. LN patients showed higher SLEDAI (6–32) as compared to SLE patients
without renal manifestations and had SLEDAI between 6–23. Fc γ RIIA polymorphic frequency in SLE patients was R131/H131
(67.5%), R131/R131 (20%) and H131/ H131 (12.5%) as against that of normal population (62.5%, 10%, and 27.5%), respectively.
Sixty two patients (77.5%) showed positivity for anti-C1q antibodies. LN patients showed elevated levels of anti-C1q antibodies
(258.2u/ml±38.5U/mL) as compared to SLE patients without nephritis (134.6±24.6U/mL). Among anti-C1q positive patients,
71% had R131/H131 genotype, 22.6% had R131/R131 and remaining 6.4%, patients had H131/H131 genotype. All anti-C1q
positive patients with R131/R131 genotype had elevated levels of anti-C1q antibodies (>100U/ml), whereas among anti-C1q
negative patients, none had R131/R131 genotype. Conclusion. This ﬁrst report on Indian SLE patients supports the hypothesis that
Fc γ RIIA R131 variant over expression may constitute a susceptibility factor for development of severe SLE manifestations in LN
patients.
1.Introduction
Genes associated with immune complex clearance, such as
Fc receptors for IgG (Fc γ R), have been described in the
past. Recent interest is focused on possibility that genetically
determined polymorphisms in structure and function of
Fc γ receptors on phagocytic cells may be important in
pathogenesis of Systemic Lupus Erythematosus (SLE). An
increased association of Fc γ RIIA gene polymorphism in
SLE patients with renal involvement has been demonstrated.
Two diﬀerent alleles encode for Fc γ IIA receptors (R131,
H131) (expressed on most leukocytes and on platelets) with
diﬀering capacities to bind human IgG2. Antibodies of IgG2
class are eﬃciently recognized by the H131 allele of Fc γ R
IIA. In contrast, Fc γ R IIA-R131 allele is found to have least
binding with IgG2 and is associated with an increase risk for
renal disease [1, 2].
C1q is the ﬁrst component of complement classical
pathway. It plays a critical role in clearance of immune
complexes and apoptotic bodies from tissues and organs.
Anti-C1q antibodies are immunoglobulins that bind to
the collagenous portion of C1q via their antigen binding
region (Fab). Anti-C1q antibodies have been found in
several infectious autoimmune diseases. In SLE, which is a
prototypicimmunecomplexdisease,anti-C1qantibodiesare
involved in immunopathogenesis. Anti-C1q antibodies bind
to glomerular immune complex deposits, enhancing com-
plement activation and this leads to subsequent tissue injury.
Renal deposition of C1q is a characteristic of proliferative
lupus nephritis (LN). Anti-C1q antibody titers are increased2 Autoimmune Diseases
Figure 1: Classical Patterns of Anti-Nuclear Antibodies (Row 1: Left to Right. Nuclear Homogenous, Coarse Speckled and Peripheral
Pattern); Row 2: Left to right. Anti-double stranded antibodies (anti-dsDNA), Anti-Neutrophil Cytoplasmic antibodies (ANCA).
in LN patients and rising titers are correlated with relapse of
nephritis [3–6].
Fc γ RIIA R131 phenotype and its association with
susceptibility to both infection and autoimmunity have been
reported in the literature. The presence of Fc γ RIIA R131
allele is associated with susceptibility to the development
of glomerulonephritis in SLE. There are sporadic reports
available on presence of Fc γ RIIA R131 variant and its
association with an increase risk of renal disease in SLE
patients with anti-C1q antibodies [7–10]. The study was
designed to ﬁnd out Fc γ RIIA genotype frequencies in
Indian SLE patients and normal healthy controls. We also
tried to evaluate the association of Fc γ RIIA genotypes, anti-
C1q antibody positivity with clinical manifestation of the
patient with LN.
2.MaterialandMethods
2.1. Subjects. Eighty SLE patients, including 53 renal biopsy-
proven cases of LN and 27 cases of SLE without clinical
evidence of nephritis (consistently normal renal function)
were selected for this study over a period of 2 years. The
details of clinical, histopathological, and laboratory ﬁndings
were recorded. This retrospective study was carried out after
obtaining the requisite Ethics Committee permission. SLE
patients were diagnosed based on the American College
of Rheumatology ACR criteria. SLE disease activity was
assessed in all these patients by the SLE Disease Activity
Index (SLEDAI). All the patients were in active stage of
disease and were untreated when included in the study
[11, 12].
Patients had no history of taking any drugs such
as hydralazine and propylthiouracil. Pregnant or post-
menopausal women were excluded. Eighty age matched
healthy subjects were used as normal controls. Blood was
collected after obtaining informed consent and sera were
stored in aliquots at −80
◦C until tested. Renal biopsies
were examined by light microscopy with hematoxylin, eosin
and periodic Schiﬀ (PAS) staining and by immunoﬂuores-
cence microscopy using anti-IgG, anti-IgM, anti-IgA, anti-
C3, anti-C4, and anti-ﬁbrinogen ﬂuorescein isothiocyanate
conjugate (FITC). In LN patients the renal histology was
classiﬁed according to WHO criteria [13].
2.2. Methods. Anti-C1q antibodies were detected using
anti-C1q EIA kit (Binding Site, UK). Levels of anti-C1q
antibodies below 8U/mL were taken as negative while
levels above 8U/mL were considered as positive. The
measuring range varied between 1.23–100U/mL. Values
greater than this range were interpreted as >100U/mL.
Anti-nuclear antibodies (ANA) were tested using Bio Rad
kit where HEP-2 cell line was used as a substrate. Results
were recorded using a ﬂuorescence microscope (Nikon,
Optiphot II). Conﬁrmation of unusual and rare ANA
patterns was done using a Confocal Laser Scanning Micro-
scope (Karl, Zeiss, LSM -510). Anti-Neutrophil cytoplas-
mic antibodies (ANCA) and anti-double stranded DNA
(Anti-dsDNA) were detected using Euroimmune, Lubeck
kit. (Figure 1) Anti-Histone antibodies were detected by
ELISA.
ThegenomicDNAwasextractedusingstandardprotocol
[14]. Fc γ RIIA genotyping was performed using 25μlP C RAutoimmune Diseases 3
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Figure 2: Agarose gel electrophoresis Fc γ IIA polymorphism.
reaction containing 100ng of genomic DNA, 15mMMgCl2,
200μMd N T P ,a n d0 . 5Uo fTaq polymerase (Ampli Taq
Gold, Perkin Elmer, CA); 0.5μM H131-speciﬁc sense primer
(5 -ATC CCA GAA ATT CTC CCA-3 )o r0 . 5 μM R131-
speciﬁc sense primer (5 -ATC CCA GAA ATT CTC CCG-3 )
with 0.5μM common antisense primer (5 -CAA TTT TGC
TGC TAT GGG C-3 ) was used. Human growth hormone
(HGH) was used as internal control. The forward primer
wasHGH-1(5 -CAGTGCCTTCCCAACCATTCCCTTA-
3 ) and reverse primer was HGH-2 (5 -ATC CAC TCA CGG
A T TT C TG T TG T GT T TC - 3  ). The PCR conditions were
as follows: The initial denaturation was carried out at 95
◦C
for 5min. Next 10 cycles consisted of 95
◦C-1min, 57
◦C-
2min, and 72
◦C-1min; and then to enhance the sensitivity,
22 cycles of 95
◦C-1min, 57
◦C-2min, and 72
◦C-1min were
carried out. Final extension was carried out at 72
◦C-5min.
Ampliﬁed productwaslateron runon 1.5% agarosegel[15].
(Figure 2).
2.3. Statistical Analysis. Continuous variables are expressed
as mean±SD. Pairs of groups were compared using student’s
“t” test for normally distributed continuous distribution.
The “X2” test was used for the categorical variables as
needed. Statistical signiﬁcance was set at P ≤ .05.
2.4. Results. Of 80 female patients, 53 patients (66.3%) were
LN and the remaining 27 patients (33.7%) were SLE without
nephritis. Renal histopathology of LN patients revealed that
34 patients (64.2%) were DPGN (Class IV), 16 (30.2%)
were FPGN (Type III), and 3 (5.7%) were MPGN (Type,
V). LN patients showed slightly higher SLEDAI (6 to 32)
as compared to SLE patients without renal involvement
(6 to 23). Table 1 gives demographic details of anti-C1q
positive and anti-C1q negative groups. Out of 80 patients
tested for anti-C1q antibodies, 62 patients (77.5%) had
anti-C1q antibodies of which 52 (76.4%) had anti-C1q
values >100U/mL. Elevated levels of anti-C1q antibodies
258.2U/mL ± 38.5U/mL were detected in LN patients as
Table 1: Demographic data of anti-C1q positive and anti-C1q
negative patients.
Parameters
Anti-C1q
positives
(n = 62)
Anti-C1q
negatives
(n = 18)
Mean age in years
Range 18–45 16–38
(Mean ±SD) 30.6 ± 10.82 7 .5 ±9.5
SLE duration in months
Range 6–18 6–15
(Mean ±SD) 8.6 ± 3.29 .0 ±2.5
SLEDAI
Range 6–32 6–23
(Mean ±SD) (6.0 ± 6.8) (5.8 ±6.5)
Lupus Nephritis (n = 53) 47 (88.7%) 6 (11.3%)
FPGN (Type III) (n = 16) 14 2
DPGN (Type IV) (n = 34) 30 4
MPGN (Type V) (n = 3) 30
SLE without nephritis (n = 27) 15 (55.5%) 12 (44.4%)
compared to 134.6 ± 24.6U/mL in SLE without nephritis.
Eighteen patients (22.5%) showed absence of anti-C1q
antibodies.
Details of Fc γ IIA genotyping in SLE patients and
normal controls are given in Table 2. Among normal
individuals, 10% of cases showed homozygosity for R131
allele (R131/R131) while 27.5% were homozygous for
H131 allele (H131/H131) and the remaining 62.5% showed
heterozygosity for both the alleles (R131/H131). Among
SLE patients 16 (20%) showed homozygosity for R131
allele (R131/R131) while 10 (12.5%) patients were homozy-
gous for H131 allele (H131/H131) and the remaining
54 patients (67.5%) showed heterozygosity for both the
alleles (R131/H131). Comparison of Fc γ IIA genotyping
with anti-C1q antibodies was carried out in 62 anti-C1q
positive patients. Fourteen patients (22.6%) homozygous
for R131 allele showed elevated anti-C1q antibody levels
(>100U/mL). Among 44 patients showing heterozygosity
for R131/H131, 35 (79.6%) showed elevated anti-C1q anti-
body levels (>100U/mL) and remaining 9 patients (20.4%)
had equivocal values for anti-C1q antibodies. H131/H131
homozygosity was found in only 4 patients (6.4%) that
were positive for anti-C1q antibodies. It was observed that
among 18 anti-C1q negative patients, none had R131/R131
genotype, 14 patients (77.8%) were R131/H131 heterozy-
gous, and 4 patients (22.2%) had H131/H131 homozygous
genotype.
Table 3 gives distribution of Fc γ RIIA genotypes and
SLEDAI scores in 80 SLE patients. It was observed that
28 patients (35%) had severe disease activity (SLEDAI
>18), 40 patients (50%) had moderate disease activity
(SLEDAI 8 to 18), and 12 patients had mild disease activity
(SLEDAI <8). It was observed that 10/16 patients (62.5%)4 Autoimmune Diseases
Table 2: Fc γ RIIA genotyping in Indian SLE patients and normal controls.
Population R131 H131 R131/R131 R131/H131 H131/H131
Normal Controls 0.4 0.6 8 50 22
(n = 80) (10%) (62.5%) (27.5%)
All SLE 0.55 0.45 16
∗ 54 10
∗
(n = 80) (20%) (67.5%) (12.5%)
Lupus Nephritis 0.55 0.45 10 38 5 ∗
(n = 53) (18.9%) (71.7%) (9.4%)
SLE without 0.52 0.48 6 16 5
nephritis (n = 27) (22.2%) (59.3%) (9.4%)
Anti-C1q positives 0.57 0.43 14 44 4
(n = 62) (22.6%) (71.0%) (6.4%)
Anti-C1q 0.42 0.58 — 14 4
Negatives (n = 18) (0%) (77.8%) (22.2%)
(∗Signiﬁcant “P”v a l u e:P<. 05)
Table 3: Distribution of Fc γ RIIA genotypes and SLEDAI in SLE
patients.
Fc γ IIA genotype Mild (<8) Moderate (8–18) Severe (>18)
R131/R131
(n = 16)
24 1 0
R131/H131
(n = 54)
10 26 18
H131/H131
(n = 10)
01 0 0
Total (n = 80) 12 (15%) 40 (50%) 28 (35%)
having Fc γ IIA R131/R131 genotype had severe disease
activity, whereas 28/56 patients (50%) having Fc γ IIA
R131/H131 genotype had moderate disease. Table 4 gives
the correlation of Fc γ IIA polymorphism with clinical
characteristics, anti-C1q antibodies, and other autoantibod-
ies.
3. Discussion
Receptors for the Fc domains of IgG (Fc γ R) play a critical
role in linking humoral and cellular immune responses.
Diﬀerent Fc γ receptor genes may contribute to infectious
and immune related diseases in various ethnic populations.
Polymorphisms in Fc γ R gene mainly Fc γ R IIA, IIB, IIIA,
and IIIB have been identiﬁed as genetic factors inﬂuencing
susceptibility to disease. Activated and inhibitory Fc γ Rs
seem to play an important role in pathogenesis of SLE,
initiation of autoimmunity, subsequent development of
inﬂammatory lesions, and ﬁnally immune complex (IC)
clearance mechanisms [10].
This is the ﬁrst report from India identifying Fc γ RIIA
genotype frequencies and their association with anti-C1q
antibodies in LN and SLE without nephritis, patients. Anti-
C1q antibodies have been found to correlate with renal
disease activity in SLE patients and consequently rising titers
may be predictive for ensuring relapses or ﬂares of LN [16,
17].LeeandMadaiohadreportedanimportanceofanti-C1q
antibody detection as a new measure for renal involvement
[18]. For LN, the critical issues include identifying these
patients at risk for ﬂare, progressive nephritis and develop-
ment of end stage renal disease. A higher prevalence of anti-
C1qantibodieshasbeenreportedinLN[18].Ithadalsobeen
shown that the absence of anti-C1q antibodies excludes a
diagnosis of LN, whereasincreases in levels may predict renal
ﬂares [19, 20].
Bazilio et al. had reported an apparent skewing towards
Fc γ IIA R 131 genotype in Brazilian SLE patients with
class III and IV types as compared to controls where
low aﬃnity Fc γ IIA R 131 variant is found not only
associated with proliferative GN but also with a more
intense IgG2 glomerular deposition [8]. Fang et al. had
reported the prevalence of anti-C1q antibodies in DPGN
cases of LN. It was reported that IgG2 subclass of anti-
C1q antibodies might be pathogenic and IgG3 subclass of
anti-C1q might be more speciﬁc bio-marker for monitoring
disease activity [21]. Maura et al. had reported a positive
correlation between high titres of anti-C1q antibodies, and
SLEDAI scores in Brazilian SLE patients and had shown an
association of anti-C1q antibodies with LN [22]. Our study
also supported this ﬁnding. Trendelenburg et al. reported
a very high incidence (97.2%) of anti-C1q antibodies in
patients with proliferative LN compared with 35% of SLE
patients with inactive LN and 25% in SLE patients without
nephritis, suggesting that a negative test result for anti-
C1q antibodies almost excludes active nephritis indicating a
pathogenic role of anti-C1q antibodies [16]. The pathogenic
role of IgG2 subclass of anti-C1q antibodies may relate
to impaired IC clearance by mononuclear phagocyte sys-
tem.
In a Korean study it was shown that LN was less frequent
in Fc γ R IIA R131/H131 heterozygous and H131/H131Autoimmune Diseases 5
Table 4: Correlation of Fc γ RIIA polymorphism with clinical proﬁle and autoantibodies in SLE patients.
Organ involvement Total SLE (n = 80) R131/R131 (n = 16) R131/H131 (n = 54) H131/H131 (n = 10)
Rash 50 14 32 4
Photosensitivity 42 14 26 2
Oral ulcers 18 6 5 1
Arthritis 45 12 31 2
Serositis 8 5 3 0
Renal 53 10 38 5
Hematolgical 10 3 7 0
Neurological 5 2 3 0
Autoantibodies
ANA 80 16 54 10
Anti-dsDNA 72 14 52 6
ANCA 16 10 6 0
Anti-Histone 28 18 8 2
Anti-C1q 68 12 42 4
homozygous patients as compared to R131/R131 homozy-
gous patients. Studies on Dutch and African-American
SLE patients had further strengthened this hypothesis of
association of Fc γ R IIA R131/R131 homozygosity with
LN [8]. Norsworthy et al. had also reported similar ﬁndings
in Caucasoid patients where a close association between Fc
γ R IIA R131 variant, anti-C1q antibodies and glomeru-
lonephritis was reported. This may be due to the failure of
IC clearance of anti-C1q autoantibodies that are pathogenic
in nature [9]. Similarly, ﬁndings from our study also support
that Fc γ R IIA R131 constitutes a susceptibility factor for the
development of severe SLE that aﬀects the kidney.
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